Evidence map›Paper›PMID 36118249›Full record

ArticleJCSM rapid communications

Muscle wasting in cancer: opportunities and challenges for exercise in clinical cancer trials.

Ciaran M Fairman, Simon Lønbro, Thomas D Cardaci, Brandon N VanderVeen, Tormod S Nilsen, Angela E Murphy

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCSM rapid communications. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Factors affecting pretransplant muscle strength in allogeneic stem cell transplant candidates prior transplantation.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  19. Correlates and predictors of sarcopenia among men with metastatic castrate-resistant prostate cancer.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Ciaran M FairmanDepartment of Exercise Science, University of South Carolina, Columbia, South Carolina 29033, USA.
Simon LønbroDepartment of Public Health, Section for Sports Science, Aarhus University, Aarhus, Denmark.
Thomas D CardaciDepartment of Exercise Science, University of South Carolina, Columbia, South Carolina 29033, USA.
Brandon N VanderVeenDepartment of Pathology, Microbiology and Immunology, School of Medicine, University of South Carolina, Columbia, South Carolina, USA.
Tormod S NilsenDepartment of Physical Performance, Norwegian School of Sports Sciences, Oslo, Norway.
Angela E MurphyDepartment of Pathology, Microbiology and Immunology, School of Medicine, University of South Carolina, Columbia, South Carolina, USA.
University of South Carolina · USAarhus University · DKNorwegian School of Sport Sciences · NO

Funding

Development of Dietary Quercetin to Treat Muscle Wasting DisordersR43AT011171 · NCCIH · ACEPRE, LLC · PI VANDERVEEN, BRANDON, VELAZQUEZ, KANDY T · 2020 to 2021
$352k
NCCIH NIH HHS R43 AT011171
6 · The paper itself

Abstract

Background: Low muscle in cancer is associated with an increase in treatment-related toxicities and is a predictor of cancer-related and all-cause mortality. The mechanisms of cancer-related muscle loss are multifactorial, including anorexia, hypogonadism, anaemia, inflammation, malnutrition, and aberrations in skeletal muscle protein turnover and metabolism. Methods: In this narrative review, we summarise relevant literature to (i) review the factors influencing skeletal muscle mass regulation, (ii) provide an overview of how cancer/treatments negatively impact these, (iii) review factors beyond muscle signalling that can impact the ability to participate in and respond to an exercise intervention to counteract muscle loss in cancer, and (iv) provide perspectives on critical areas of future research. Results: Despite the well-known benefits of exercise, there remains a paucity of clinical evidence supporting the impact of exercise in cancer-related muscle loss. There are numerous challenges to reversing muscle loss with exercise in clinical cancer settings, ranging from the impact of cancer/treatments on the molecular regulation of muscle mass, to clinical challenges in responsiveness to an exercise intervention. For example, tumour-related/treatment-related factors (e.g. nausea, pain, anaemia, and neutropenia), presence of comorbidities (e.g. diabetes, arthritis, and chronic obstructive pulmonary disease), injuries, disease progression and bone metastases, concomitant medications (e.g., metformin), can negatively affect an individual's ability to exercise safely and limit subsequent adaptation. Conclusions: This review identifies numerous gaps and oppportunities in the area of low muscle and muscle loss in cancer. Collaborative efforts between preclinical and clinical researchers are imperative to both understanding the mechanisms of atrophy, and develop appropriate therapeutic interventions.

Indexed as

CachexiaMuscle lossResistance exerciseSarcopenia

Identifiers

PMID36118249
PMCPMC9481195
OpenAlexW4200318408

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.